1258277-12-1

Basic information

• Product Name: (2S,5S)-2,5-Dimethylmorpholine
• Synonyms: (2S,5S)-2,5-Dimethyl-morpholine HCl
• CAS NO: 1258277-12-1
• Molecular Formula: C6H13NO
• Molecular Weight: 115.17352
• Mol File: 1258277-12-1.mol

Chemical Properties

• Boiling Point: 151℃
• Flash Point: 50℃
• Appearance: /
• Density: 0.862
• PKA: 9.07±0.60(Predicted)
• CAS DataBase Reference: (2S,5S)-2,5-Dimethylmorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,5S)-2,5-Dimethylmorpholine(1258277-12-1)
• EPA Substance Registry System: (2S,5S)-2,5-Dimethylmorpholine(1258277-12-1)

Safety Data

• Hazardous Substances Data: 1258277-12-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2S,5S)-2,5-Dimethylmorpholine is used as a catalyst and a reagent in organic synthesis for its ability to facilitate various chemical reactions. Its presence can enhance the efficiency and selectivity of reactions, making it an essential component in the synthesis of complex organic molecules.
Used in Pharmaceutical Production:
(2S,5S)-2,5-Dimethylmorpholine is used as an important building block in the production of pharmaceuticals. Its unique structure and reactivity make it suitable for the synthesis of various drug molecules, contributing to the development of new and effective medications.
Used in Agrochemical Production:
In the agrochemical industry, (2S,5S)-2,5-Dimethylmorpholine is used as a key intermediate in the synthesis of various agrochemicals. Its incorporation into these products helps improve their efficacy and performance in agricultural applications.
Used in Fine Chemicals Manufacturing:
(2S,5S)-2,5-Dimethylmorpholine is utilized as a versatile building block in the manufacturing of fine chemicals. Its unique properties allow it to be incorporated into a wide range of specialty chemicals, enhancing their performance and functionality.
Used as a Solvent in Industrial Processes:
(2S,5S)-2,5-Dimethylmorpholine is also used as a solvent in some industrial processes. Its ability to dissolve a variety of substances and its compatibility with different materials make it a valuable component in various industrial applications.

Upstream product

• 115893-42-0 (β-hydroxy-isopropyl)-(2-hydroxy-propyl)-amine 
• 106-62-7 Dipropylene glycol 
• 115206-98-9 (2S,5S)-2,5-Dimethyl-3-oxoperhydro-1,4-oxazin 
• 115206-95-6 (1'S,2S)-2-Chlor-N-(2'-hydroxy-1'-methylethyl)propionsaeureamid 
• 115206-95-6 (R)-2-Chloro-N-((S)-2-hydroxy-1-methyl-ethyl)-propionamide 
• 110-97-4 diisopropanolamine 
• 1235469-32-5 (2R,5S)-2,5-dimethyl-4-tosylmorpholine 
• 1235469-35-8 (2R,5R)-benzyl 2,5-dimethylmorpholine-4-carboxylate 

Relevant articles and documents

Preparation method of high-purity cis-2,6-dimethylmorpholine

The invention relates to the technical field of chemical synthesis of medicines, and discloses a preparation method of high-purity cis-2,6-dimethylmorpholine. The method comprises the following steps:subjecting a cis-2,6-dimethylmorpholine-rich mixture of cis-2,6-dimethylmorpholine, trans-2, 6-dimethylmorpholine, cis-2,5-dimethylmorpholine and trans-2,5-dimethylmorpholine to salt formation with micromolecular aliphatic carboxylic acid in an ester solvent, and carrying out recrystallizing to obtain cis-2,6-dimethylmorpholine carboxylate; and dissociating the cis-2,6-dimethylmorpholine carboxylate by using a strong alkaline substance to obtain the high-purity cis-2,6-dimethylmorpholine. According to the method disclosed by the invention, environment-friendly ethyl acetate, isopropyl acetateand butyl acetate are used as reaction solvents and also used as recrystallization solvents, so realization of green production is facilitated which reduction of pollution is realized, impurity content is effectively controlled, finished product purity reaches 99.9% or above, used acids and solvents are friendly to environment, and the method is suitable for industrial production.

Purification method of cis-2, 6-dimethylmorpholine

The invention discloses a purification method of cis-2, 6-dimethylmorpholine, and the method comprises the following steps: providing a mixture of cis-2, 6-dimethylmorpholine, trans-2, 6-dimethylmorpholine, cis-2, 5-dimethylmorpholine and trans-2, 5-dimethylmorpholine, reacting the mixture with carboxylic acid in an ester solvent, and crystallizing to obtain cis-2, 6-dimethylmorpholine carboxylate, wherein the content of the cis-2, 6-dimethylmorpholine in the mixture is greater than or equal to 80 mol%, and hydrolyzing the cis-2, 6-dimethylmorpholine carboxylate with an alkaline substance to obtain the cis-2, 6-dimethylmorpholine. According to the method, the raw material is easy to obtain, the raw material selection range is wider, the process is simple and convenient, the cost is low, the used reagent is environmentally friendly, the purity of the finished product is high, and the use requirements of medicine and other fields can be met.

Steric effects in the catalytic amination of γ-, δ-, and ε-glycols

The amination of butane-1,4-diol, isomeric dipropylene glycols, and cyclohexane-1,4-diyldimethanol in the presence of nickel/copper/chromium catalysts has been studied. The effect of the initial glycol structure on the reaction selectivity has been estima

A concise and efficient synthesis of substituted morpholines

A simple and efficient method has been developed for the synthesis of substituted morpholines by a sequence of coupling, cyclization, and reduction reactions of easily available amino alcohols and α-halo acid chlorides. Various mono-, di-, and trisubstituted morpholines, spiro morpholines, and ring-fused morpholines, as well as morpholine homologues, were synthesized in good to excellent yields by a single methodology under similar reaction conditions. The method was also used in a multigram synthesis of (3S)-3-methylmorpholine.

Phthalazine, aza- and diaza-phthalazine compounds and methods of use

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.